📉 
DXCM – Bearish Setup Developing
DexCom (DXCM) took a major hit today after cutting revenue guidance by 12% to $1.2B.
A 30% drop in user base triggered an 11% selloff, confirming structural weakness.
Options flow shows strong bearish positioning:
🔻 3,000-lot block of Nov $65 puts traded, reinforcing downside pressure.
Implied Volatility sits around 51.5%, signaling sustained volatility ahead.
Chart Outlook (see attached):
Price is breaking down from key levels and heading into lower demand zones.
Institutional forecast models point toward a target near $49–50 (-26%) in the next 90 days.
Sentiment models (WaverVanir DSS) show only a minor short-term bounce possible, but longer-term trajectory remains bearish.
📊 Key Levels:
Resistance: $75 – $82 (supply zone)
Support: $65 (near-term), $52 – $50 (major demand zone)
Risk/Reward favors shorts into weakness.
⚠️ Bias: Strong Sell / Short Continuation
Expect further downside with elevated volatility as the market reprices guidance and user metrics.
DXCM – Bearish Setup DevelopingDexCom (
DXCM) took a major hit today after cutting revenue guidance by 12% to $1.2B.A 30% drop in user base triggered an 11% selloff, confirming structural weakness.
Options flow shows strong bearish positioning:
🔻 3,000-lot block of Nov $65 puts traded, reinforcing downside pressure.
Implied Volatility sits around 51.5%, signaling sustained volatility ahead.
Chart Outlook (see attached):
Price is breaking down from key levels and heading into lower demand zones.
Institutional forecast models point toward a target near $49–50 (-26%) in the next 90 days.
Sentiment models (WaverVanir DSS) show only a minor short-term bounce possible, but longer-term trajectory remains bearish.
📊 Key Levels:
Resistance: $75 – $82 (supply zone)
Support: $65 (near-term), $52 – $50 (major demand zone)
Risk/Reward favors shorts into weakness.
⚠️ Bias: Strong Sell / Short Continuation
Expect further downside with elevated volatility as the market reprices guidance and user metrics.
Note
Note
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.